Sorafenib-induced severe acute hepatitis in a stable liver transplant recipient.
Herden
Uta
U
Fischer
Lutz
L
Schäfer
Hansjörg
H
Nashan
Björn
B
von Baehr
Volker
V
Sterneck
Martina
M
D000208:Acute Disease; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001557:Benzenesulfonates / Q000009:adverse effects* / Q000627:therapeutic use; D001663:Bilirubin / Q000097:blood; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy / Q000601:surgery*; D056486:Chemical and Drug Induced Liver Injury / Q000175:diagnosis*; D006526:Hepatitis C / Q000601:surgery*; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000601:surgery*; D016031:Liver Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000009:adverse effects* / Q000627:therapeutic use; D000077157:Sorafenib; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib; D001663:Bilirubin